DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Meningococcal Infections
Meningococcal Meningitis
Meningitis

Interventions: Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

First Posted Date: 2016-04-27

Last Posted Date: 2022-04-05

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 810

Registration Number: NCT02752906

Locations: 🇺🇸
Investigational Site Number 026, Mesa, Arizona, United States
🇺🇸
Investigational Site Number 013, Bardstown, Kentucky, United States
🇺🇸
Investigational Site Number 021, Kettering, Ohio, United States

and more 27 locations

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Phase 2

Completed

Conditions: Dengue Fever
Dengue Hemorrhagic Fever
Human Immunodeficiency Virus

Interventions: Biological: Placebo (NaCl 0.9%) vaccine group
Biological: CYD Dengue Vaccine

First Posted Date: 2016-04-18

Last Posted Date: 2024-07-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 133

Registration Number: NCT02741128

Locations: 🇧🇷
Investigational Site Number :0760004, Natal, Rio Grande Do Norte, Brazil
🇧🇷
Investigational Site Number :0760002, Nova Iguaçu, Rio De Janeiro, Brazil
🇧🇷
Investigational Site Number :0760003, Sao Paulo, Brazil

and more 1 locations

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Completed

Conditions: Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions: Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

First Posted Date: 2016-03-04

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 100

Registration Number: NCT02699840

Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.

Phase 3

Completed

Conditions: Hepatitis B

First Posted Date: 2016-03-03

Last Posted Date: 2022-04-06

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 150

Registration Number: NCT02697474

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

Phase 2

Completed

Conditions: Meningitis
Meningococcal Infections
Meningococcal Meningitis

Interventions: Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

First Posted Date: 2015-12-29

Last Posted Date: 2018-01-08

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 224

Registration Number: NCT02640404

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Phase 4

Completed

Conditions: Meningococcal Meningitis
Meningococcal Infections
Meningitis

Interventions: Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

First Posted Date: 2015-12-17

Last Posted Date: 2016-11-06

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 110

Registration Number: NCT02633787

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Phase 2

Completed

Conditions: Dengue Hemorrhagic Fever
Dengue Fever

Interventions: Biological: CYD Dengue Vaccine
Biological: Placebo (Sodium chloride 0.9%)

First Posted Date: 2015-12-11

Last Posted Date: 2022-03-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1050

Registration Number: NCT02628444

Locations: 🇨🇴
Investigational Site 102, Barranquilla, Colombia
🇵🇭
Investigational Site 203, Manila, Philippines
🇨🇴
Investigational Site 103, Medellin, Colombia

and more 3 locations

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Phase 2

Completed

Conditions: Dengue Hemorrhagic Fever
Dengue Fever

Interventions: Biological: CYD Dengue Vaccine (5-dose formulation)
Biological: Placebo, NaCl 0.9%

First Posted Date: 2015-12-08

Last Posted Date: 2022-03-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 251

Registration Number: NCT02623725

Locations: 🇧🇷
Investigational Site Number 001, Vitoria, Brazil
🇨🇴
Investigational Site Number 002, Bucaramanga, Colombia
🇭🇳
Investigational Site Number 003, Tegucigalpa, Honduras

and more 2 locations

Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

Not Applicable

Completed

Conditions: Hepatitis B

Interventions: Biological: DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
Biological: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines

First Posted Date: 2015-11-20

Last Posted Date: 2018-03-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 122

Registration Number: NCT02610348

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Phase 4

Completed

Conditions: Meningococcal Infections
Meningococcal Meningitis
Meningitis

Interventions: Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate

First Posted Date: 2015-10-29

Last Posted Date: 2017-11-06

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 60

Registration Number: NCT02591290

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy